FN2 Earnings Intelligence
IQVIA Holdings Inc. earnings overview
Latest IQVIA Holdings Inc. (IQV) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
IQVIA Holdings Inc.
The supplied analysis supports a constructive near-term operating thesis: AI adoption, stronger win rates, bookings, drug launches, and biotech funding are supporting growth, while acquisition contribution adds to the outlook. The thesis is tempered by backlog-quality adjustments, pass-through margin effects, and the need for continued AI adoption.
IQVIA Holdings Inc.
The Q2 evidence supports a constructive operating thesis for IQVIA: resilient outsourcing demand, stronger bookings, and expanding AI-enabled services supported growth, margin improvement, and a higher full-year outlook. The thesis is tempered by backlog quality, pass-through mix, FX, and compliance risks.
IQVIA Holdings Inc.
IQVIA's Q1 FY2026 results reinforce an AI-driven growth narrative, with record revenue of $4.15B, a $34.2B backlog, and AI agent deployments scaling to 192 across 64 use cases. The raised full-year EPS guidance to $12.65-$12.95 and confident management tone indicate continued operational momentum. Key questions center on whether FX tailwinds can persist and how pass-through mix affects profitability optics.
IQVIA Holdings Inc.
The current analysis supports a constructive operating thesis: strong bookings and backlog, AI-enabled offerings, data services, acquisitions, and raised 2026 guidance point to continued demand. The case is moderated by unresolved questions about margins, AI disruption, funding-sensitive R&D demand, and the durability of backlog.
IQVIA Holdings Inc.
IQVIA's Q3 analysis supports a constructive but conditional view: demand indicators, cash generation and AI investment strengthened, while pricing, funding cycles, execution and regulatory complexity remain constraints to monitor.
IQVIA Holdings Inc.
The supplied analysis supports a constructive but qualified view: demand for life-sciences analytics and clinical services appears resilient, with TAS growth, a record R&DS backlog, improved win rates, and AI deployment as supporting evidence. The thesis remains exposed to macro uncertainty, pricing pressure, mix-driven margin compression, FX normalization, and delayed trial activity.
IQVIA Holdings Inc.
The supplied analysis supports a balanced view: strong TAS execution, AI adoption, strategic partnerships, and record backlog support the growth case, but trial delays, cancellations, pricing pressure, and acquisition economics weaken near-term visibility.
IQVIA Holdings Inc.
The supplied analysis supports a constructive but qualified view: steady demand, strong R&DS bookings, AI/ML adoption, and acquisitions can support growth, but pricing pressure, mix effects, trial cancellations, and execution risks may limit margin conversion.
Get the IQV recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.